Richard Makara Net Worth

Mr. Richard Makara biography

Richard Makara is the VP, Head of Accounting, Controller & Principal Accounting Officer at Cara Therapeutics Inc.

What is the salary of Mr Makara?

As the VP, Head of Accounting és Controller & Principal Accounting Officer of Cara Therapeutics Inc, the total compensation of Mr Makara at Cara Therapeutics Inc is $420,429. There are 8 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.

How old is Mr Makara?

Mr Makara is 50, he's been the VP, Head of Accounting és Controller & Principal Accounting Officer of Cara Therapeutics Inc since . There are 12 older and 5 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.

What's Mr Makara's mailing address?

Richard's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 107 ELM STREET, 4 STAMFORD PLAZA, STAMFORD, CT, 06902.

Insiders trading at Cara Therapeutics Inc

Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum és Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.

What does Cara Therapeutics Inc do?

cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Cara Therapeutics Inc executives and stock owners

Cara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Joana Goncalves,
  Chief Medical Officer
• Derek Chalmers,
  President, Chief Executive Officer, Director
• Frederique Menzaghi,
  Senior Vice President, Research and Development, Chief Scientific Officer
• Scott Terrillion,
  Chief Compliance Officer, General Counsel, Secretary
• Dr. Derek T. Chalmers D.Sc., Ph.D.,
  Co-Founder & Sr. Advisor
• Dr. Frédérique Menzaghi,
  Chief Scientific Officer and Sr. VP of R&D
• Dr. Joana Goncalves,
  Chief Medical Officer
• Scott M. Terrillion,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Richard Makara,
  VP, Head of Accounting, Controller & Principal Accounting Officer
• Martin Vogelbaum,
  Lead Independent Director
• Harrison Bains,
  Independent Director
• Christopher Posner,
  Independent Director
• Jeffrey Ives,
  Independent Director
• Thomas Charles Reilly,
  Chief Financial Officer
• Christopher A. Posner,
  Pres, CEO & Director
• Susan Shiff,
  Director
• Richard Makara,
  Vice President, Head of Accounting & Controller
• Thomas Reilly,
  Chief Financial Officer
• Eric Vandal,
  Sr. VP of Commercial
• Dr. Michael E. Lewis Ph.D.,
  Co-Founder & Chief Scientific Advisor
• Ventures Vi Lprmv Vi, L.L.C...,
  
• Josef Schoell,
  Chief Financial Officer
• Dean Slagel,
  Director
• Ventures Vi Lprmv Vi, L.L.C...,
  
• Michael E Lewis,
  Chief Scientific Advisor
• Joseph William Stauffer,
  Chief Medical Officer
• Robert Medve,
  Chief Medical Officer
• Ventures Vi Lp Rho Capital ...,
  
• Charles Ph.D. Moller,
  Director
• Biopharma Partners Iii Lpal...,
  
• Edward Hurwitz,
  Director
• Ryan D Maynard,
  CHIEF FINANCIAL OFFICER
• Moltke Lisa Von,
  
• Helen M Boudreau,